Kentucky Retirement Systems Has $17.64 Million Stake in Gilead Sciences, Inc. $GILD

Kentucky Retirement Systems raised its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 61.9% in the first quarter, HoldingsChannel.com reports. The firm owned 126,596 shares of the biopharmaceutical company’s stock after purchasing an additional 48,403 shares during the quarter. Kentucky Retirement Systems’ holdings in Gilead Sciences were worth $17,644,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Strategic Investment Solutions Inc. IL bought a new stake in shares of Gilead Sciences in the fourth quarter valued at approximately $25,000. Vermillion & White Wealth Management Group LLC increased its stake in Gilead Sciences by 71.4% during the 4th quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 85 shares during the period. Quattro Advisors LLC bought a new position in Gilead Sciences during the 4th quarter worth $26,000. Wealth Preservation Advisors LLC raised its holdings in Gilead Sciences by 60.0% in the 4th quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 81 shares in the last quarter. Finally, Wilkerson Advisory Group LLC raised its holdings in Gilead Sciences by 54.2% in the 1st quarter. Wilkerson Advisory Group LLC now owns 222 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 78 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences News Summary

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: UBS analyst Michael Yee reiterated a Buy rating and maintained a $175 price target, citing Gilead’s long-acting HIV pipeline and advances in pre-exposure prophylaxis (PrEP) as sources of durable growth. Michael Yee Reiterates Buy on Gilead
• Positive Sentiment: The earnings preview highlights continued strength in Gilead’s HIV franchise, rising expectations for Yeztugo, and progress in oncology. These businesses could help support revenue growth and investor sentiment if management provides constructive guidance. Gilead to Report Q2 Earnings
• Neutral Sentiment: Gilead’s CAR-T therapies remain established products, but off-the-shelf developers are targeting market segments that approved therapies do not fully address. This could expand the broader CAR-T market while also increasing competitive pressure over time. BMS and Gilead Rule in the CAR-T Space
• Negative Sentiment: Barclays lowered its Gilead price target from $155 to $145 and assigned an Equal Weight rating, signaling more limited near-term upside despite the target remaining above the current trading level. Barclays Gilead Price Target Update
• Negative Sentiment: Analyst previews warn that Gilead may report a decline in second-quarter earnings and does not appear to have the usual combination of positive earnings revisions and estimate-beat indicators. Competitive pressure in Cell Therapy is an additional concern heading into the report. Analysts Estimate Gilead to Report a Decline in Earnings
• Negative Sentiment: Atea Pharmaceuticals said its hepatitis C combination therapy matched Gilead’s drug in a pivotal Phase 3 trial. If approved, a competing oral regimen could threaten Gilead’s hepatitis C franchise, although commercialization and regulatory risks remain. Atea Hepatitis C Phase 3 Trial

Analyst Ratings Changes

Several analysts have recently issued reports on the company. Leerink Partners lowered Gilead Sciences from an “outperform” rating to a “market perform” rating and reduced their target price for the stock from $146.00 to $127.00 in a report on Tuesday, July 21st. Wall Street Zen raised Gilead Sciences from a “hold” rating to a “buy” rating in a research note on Sunday, July 12th. Citigroup upped their price objective on shares of Gilead Sciences from $156.00 to $165.00 and gave the stock a “buy” rating in a research report on Monday, April 13th. The Goldman Sachs Group increased their price objective on shares of Gilead Sciences from $125.00 to $130.00 and gave the stock a “neutral” rating in a research note on Friday, April 17th. Finally, Royal Bank Of Canada decreased their target price on shares of Gilead Sciences from $122.00 to $120.00 and set a “sector perform” rating on the stock in a report on Tuesday, July 7th. Twenty-five investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Gilead Sciences currently has an average rating of “Moderate Buy” and a consensus target price of $157.93.

Gilead Sciences Trading Down 1.2%

Shares of GILD stock opened at $132.73 on Thursday. Gilead Sciences, Inc. has a fifty-two week low of $108.46 and a fifty-two week high of $157.29. The stock’s fifty day moving average price is $129.68 and its two-hundred day moving average price is $135.84. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.77 and a current ratio of 1.97. The company has a market cap of $164.79 billion, a PE ratio of 18.08 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 EPS for the quarter, topping analysts’ consensus estimates of $1.91 by $0.12. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The company had revenue of $6.96 billion during the quarter, compared to analysts’ expectations of $6.91 billion. During the same quarter in the previous year, the firm earned $1.81 EPS. Gilead Sciences’s revenue was up 4.4% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. Equities analysts predict that Gilead Sciences, Inc. will post -0.78 EPS for the current fiscal year.

Insiders Place Their Bets

In other Gilead Sciences news, CEO Daniel Patrick O’day sold 15,000 shares of the business’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $131.46, for a total transaction of $1,971,900.00. Following the completion of the transaction, the chief executive officer owned 617,567 shares of the company’s stock, valued at approximately $81,185,357.82. The trade was a 2.37% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 28,000 shares of the stock in a transaction dated Friday, May 15th. The stock was sold at an average price of $131.29, for a total transaction of $3,676,120.00. Following the completion of the transaction, the insider directly owned 125,779 shares of the company’s stock, valued at $16,513,524.91. This trade represents a 18.21% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 67,000 shares of company stock valued at $8,687,140. 0.30% of the stock is currently owned by corporate insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.